Serologically detectable MHC and tumor-associated antigens on B16 melanoma variants and humoral immunity in mice bearing these tumors

M. Baniyash, N. I. Smorodinsky, M. Yaakubovicz, I. P. Witz

Research output: Contribution to journalArticlepeer-review

27 Scopus citations

Abstract

We compared the expression of serologically detectable MHC and tumor-associated antigens on low and high metastasis variants of B16 melanoma tumor. Complement-dependent cytotoxicity, radioimmunobinding, and quantitative absorption assays showed that with respect to both types of antigens the low metastasis variant B16-F1 expressed a higher serologically detectable antigenicity than B16-F10, its high metastasis counterpart. A reverse situation existed in terms of in vivo immunogenicity of these metastasis variants. Sera from C57BL/6 mice bearing locally growing B16-F10 tumors had a higher binding activity to B16 cells than sera from B16-F1 bearers. Accordingly, in vivo propagating B16-F10 tumors had a higher content of tumor-associated Ig than B16-F1 tumors.

Original languageAmerican English
Pages (from-to)1318-1323
Number of pages6
JournalJournal of Immunology
Volume129
Issue number3
StatePublished - 1982
Externally publishedYes

Fingerprint

Dive into the research topics of 'Serologically detectable MHC and tumor-associated antigens on B16 melanoma variants and humoral immunity in mice bearing these tumors'. Together they form a unique fingerprint.

Cite this